Introduction {#S0001}
============

Inherited platelet disorders (IPDs) are a heterogeneous group of disorders associated with normal or reduced platelet counts and bleeding diatheses of varying severities \[1,2\]. The identification of the underlying cause of IPDs is clinically challenging, and, as a consequence, a DNA-based approach has a highly important role in the investigation of these patients \[3\]. The UK Genotyping and Phenotyping of Platelets (GAPP) study recruits patients with mild bleeding who have been clinically diagnosed with a suspected platelet function disorder. However, approximately 60% of patients recruited have no apparent platelet defect, despite having a clinically significant bleeding score. A mother and son were recruited to the GAPP study with a lifelong bleeding tendency, including posttraumatic bleeding, but presented with normal platelet and platelet-rich plasma (PRP) counts (4.2 × 10^8^/mL and 3 × 10^8^/mL, respectively), normal clotting factors, and normal platelet function. Factor IX genetics were also normal; however, prothrombin consumption index was abnormal. To study these patients further, we have used a forward genetic approach by implementing whole exome sequencing (WES) focusing on nonplatelet genes.

Methods {#S0002}
=======

The mother and son were evaluated, and a clinical history was taken including bleeding scores using the International Society of Haemostasis and Thrombosis bleeding assessment tool \[4\]. Blood was obtained from both patients, PRP was isolated, and platelet function was tested using lumiaggregometry. A dual Chrono-log 460VS lumiaggregometer (Chrono-log, LabMedics, UK) was used to test patient PRP using a range of concentrations of agonists: ADP (100 µM, 30 µM and 10 µM, 3 µM, 1 µM), adrenaline (30 µM and 10 µM), arachidonic acid (2.25 mM and 1.5 mM), U46619 (3 µM and 1 µM), PAR1 agonist (100 µM, 30 µM, and 10 µM), PAR4 agonist (500 µM, 250 µM, and 100 µM), collagen (3 µg/mL, 1 µg/mL, and 0.3 µg/mL), collagen-related peptide (CRP) (1 µg/mL), and ristocetin (1.25 mg/mL and 1.5 mg/mL). Platelet ATP secretion from dense granules was also measured using the luciferase assay and agonists: ADP (100 µM), adrenaline (30 µM), U46619 (3 µM), PAR1 agonist (100 µM), PAR4 agonist (500 µM), collagen (3 µg/mL), and CRP (1 µg/mL) \[5\].

WES was performed with a minimum of 1μg DNA extracted from peripheral blood. Enrichment of the coding regions and intron/exon boundaries was completed with the SureSelect Human All Exon 50 Mb kit (Agilent Technologies, UK) according to the manufacturer's instructions and analyzed as previously described \[6\]. The novelty of filtered variants was elucidated by comparison to known variants present within dbSNP139, exome aggregation consortium (ExAC), the 1000 Genomes Project and EVS (evs.gs.washington.edu/EVS/), as well as the data generated from over 1200 exomes of in-house controls sequenced and analyzed using the same protocol \[7\]. Copy number variants were detected using ExomeDepth \[8\]. Variants were then called using a custom-made bioinformatics pipeline to determine candidate variants from the WES data as previously shown by the GAPP study \[6\]. Sanger sequencing was then performed on candidate variants to confirm the variants, thereby ruling out the possibility of false-positive results of WES.

Results {#S0003}
=======

The family pedigree in this study displays an autosomal dominant inheritance for the bleeding phenotype ([Figure 1](#F0001)). An extensive bleeding history throughout the pedigree was evident. The index case, a male III:2, suffered from hemarthroses, soft tissue, and muscle bleeding in childhood and a spontaneous rectal sheath hematoma in 2006. His mother, II:4, was admitted to hospital for 3 weeks after wisdom teeth extraction and suffered bleeding after tonsillectomy and menorrhagia requiring hysterectomy (complicated by bleeding). His grandmother, I:1, suffered from bleeding after dental extraction requiring transfusion, easy bruising, and postpartum hemorrhage. His maternal aunt, II:3, had extensive bleeding which resorted in a nephrectomy following a road-traffic accident and maternal uncle II:2 lost an eye as a result of traumatic bleeding as a child as well as suffering from bleeding post dental extraction and soft tissue and muscle bleeding.Figure 1.Identification of a *THBD* mutation in a family with a dominant form of inherited bleeding with normal platelet aggregation and secretion. Pedigree shows affected individuals as shaded symbols and asterisks (\*) indicate patients (II:4 and III:2) whose whole exomes were sequenced.

Patients' III:2 and II:4 platelet aggregation traces showed normal responses to all the concentrations of agonists that were tested. Normal platelet granule secretion values were also observed in both patients in response to all agonists (data not shown). Therefore, no defect in platelet aggregation or secretion was detected in either of the patients tested.

WES identified 26 125 variants in II:4 and 25 969 variants in III:2. The bioinformatics pipeline was used to narrow down the variants with a series of filtering steps. Following the alignment step and determining the novelty of the variants, they were filtered against a custom-made panel of 856 genes known or predicted to be associated with platelet count or function, coagulation, or endothelial cell function. The remaining variants were then filtered by frequency; variants with a minor allele frequency (MAF) of more than or equal to 0.01 were excluded as were any synonymous changes. Comparison of both patients with a MAF ≤ 0.01 reduced to a total of 17 sequence variants. Pathogenicity prediction tools (Mutation Taster, Phastcons, SIFT, Provean etc.) were then utilized and the variants were classified as outlined by the American College of Medical Genetics and Genomics (ACMG) \[9\]. Candidate sequence variants were selected and reduced on the basis of a pathogenic prediction in at least three out of four of the prediction tools. This left candidate variants in five genes: *APC, PDE3A, ACE, OCLN*, and *THBD* ([Table I](#T0001)). All previously mentioned variants were classified as being of "uncertain significance" by the ACMG except for *THBD* which was classified as "pathogenic." Sanger sequencing confirmed that the genetic variant in *THBD* (c.1611C\>A) was present in both patients.Table I.Filtering pipeline showing the filtering strategy taken while selecting genetic variants as candidates in two affected family members (II:4 and III:2) with normal platelet function following extensive laboratory testing. II:4III:2Total number of variants identified by WES26 12525 969Total number of variants (excluding synonymous) with a MAF ≤0.0123202376Shared significant variants from the panel of platelet and endothelial cell genes with a MAF ≤0.0117Total number of novel variants181152Total number of shared novel variants50Total number of shared panel genes predicted to be pathogenic using all bioinformatics tools5 (*APC, PDE3A, ACE, OCLN*, and *THBD*)

Discussion {#S0004}
==========

Extensive lumiaggregometry performed in both patients established that there was no clear platelet function defect. The *THBD* sequence variant identified in this family which encodes the protein thrombomodulin (c.1611C\>A, p.Cys537Stop) had been previously reported to cause a similar bleeding diathesis \[10,11\]. Thrombomodulin, a glycoprotein, is expressed on the surface of endothelial cells and normally serves as a cofactor for thrombin \[12\]. In a normal state, thrombomodulin forms a complex with thrombin reducing blood coagulation by activation of protein C, therefore inactivating factors Va and VIIIa, cofactors highly involved in the coagulation cascade, and promoting fibrinolysis. However, the genetic variant in these patients leads to a stop codon, resulting in premature termination of transcription and hence a truncated form of the protein. Due to the truncation, the protein is shed from the endothelial cell membrane into the blood plasma. The increase of soluble thrombomodulin promotes protein C activation and is also seen in several pathologic conditions associated with endothelial dysfunction \[13,14\]. This therefore reduces thrombin generation within a potential thrombus, resulting in the phenotype of posttraumatic bleeding \[10\]. Furthermore, this concurs with the abnormal prothrombin consumption index observed in the patients tested. This is a rare example of where a gain-of-function mutation in an anticoagulant factor causes a bleeding disorder \[11\].

Conclusions {#S0005}
===========

The genetic cause of bleeding in both patients I:2 and II:1 recruited to the GAPP study has been elucidated as a genetic variant in the gene *THBD* using next-generation sequencing. The same genetic variant in *THBD* has previously been shown to cause a bleeding phenotype within affected individuals \[10,11\]. This can, therefore, explain the cause of bleeding in II:4 and III:2 and suggests that it may be a recurrent mutation.
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